|1.||Haab, F: 3 articles (12/2009 - 12/2009)|
|2.||Costa, P: 3 articles (12/2009 - 12/2009)|
|3.||Delmas, V: 3 articles (12/2009 - 12/2009)|
|4.||Humbert, M: 3 articles (03/2009 - 10/2002)|
|5.||Simonneau, G: 3 articles (03/2009 - 10/2002)|
|6.||Edkins, Katherine: 2 articles (08/2015 - 11/2014)|
|7.||Murray, Helen B: 2 articles (08/2015 - 11/2014)|
|8.||Eddy, Kamryn T: 2 articles (08/2015 - 11/2014)|
|9.||Franko, Debra L: 2 articles (08/2015 - 11/2014)|
|10.||Krishna, Meera: 2 articles (08/2015 - 11/2014)|
|1.||Weight Loss (Weight Reduction)
11/01/1987 - "In a second trial, 29 patients were treated for 24 weeks with dexfenfluramine; average cumulative weight loss after 12 weeks in these patients (5.7 +/- 0.1 kg) was significantly greater than in the patients who had been treated initially with placebo. "
06/01/1998 - "When analysed on a completion basis, weight loss in the dexfenfluramine group was significant in females but not in males at year 4. During the 4 years of observation a cohort of 54 patients reflecting our routine clinic practice gained on average 0.35 kg. Although now withdrawn, the use of an appetite suppressant dexfenfluramine for just 3 months would appear to have a long-term advantage on weight loss in this diabetic population, although the weight lost was not associated with improvement in glycaemic control."
03/01/1995 - "After a one month 'run in' phase and six months treatment, weight loss in the dexfenfluramine group was significantly greater than placebo, 9.7 +/- 1.1 kg vs 4.9 +/- 0.9 kg (mean +/- s.e.m.); P = 0.002. "
03/01/2007 - "In conclusion, our findings show that dexfenfluramine is effective in achieving weight loss and also increases lipid peroxidation in mouse brain."
02/01/1993 - "Dexfenfluramine is effective in achieving weight loss and also improved diabetic control in obese type II diabetics over a three-month period."
09/15/1997 - "Dexfenfluramine is effective in the treatment of obesity in selected patients. "
05/01/1990 - "We conclude that inhibition of gastric emptying may contribute to the efficacy of dexfenfluramine in the treatment of obesity."
03/01/1997 - "The aim of this study was to investigate the potential of dexfenfluramine (dF) for reducing cardiovascular risk factors and improving compliance towards diet in a group of young patients hospitalized for essential obesity of high degree (BMI > or = 35). "
01/01/1997 - "The value of a one year prescription of dexfenfluramine (dF) was demonstrated by a large multicentric study performed in centres specialised in the treatment of obesity (Guy-Grand 1989). "
08/01/1996 - "Forty-two patients (20 with upper body obesity, 12 dexfenfluramine and 10 placebo; 22 with lower body obesity, 16 dexfenfluramine and six placebo) completed the 14-month study. "
12/01/1992 - "Of the agents found effective in minimizing weight gain, serotoninergic drugs, particularly dexfenfluramine, show special promise because they prevent an increase in caloric intake but do not decrease energy intake below pre-cessation levels."
04/01/2005 - "Weight gain was prevented with MTEP (3 mg/kg), and weight and adiposity loss was seen with MTEP (10 mg/kg) and dexfenfluramine. "
01/01/1997 - "Dexfenfluramine for weight gain secondary to psychotropics."
12/01/1992 - "Strategies to minimize weight gain after smoking cessation: psychological and pharmacological intervention with specific reference to dexfenfluramine."
12/01/1995 - "By 2 mo postcessation, dexfenfluramine still suppressed weight gain in comparison with placebo (P < 0.05); weight gain with fluoxetine was not differentiable from either dexfenfluramine or placebo. "
|4.||Body Weight (Weight, Body)
01/01/1993 - "The purpose of this study was to determine the effects of dexfenfluramine on body weight and post-prandial thermogenesis in obese subjects. "
01/01/1988 - "Dexfenfluramine and body weight regulation: experimental study with hoarding behavior."
01/01/1986 - "Effect of dexfenfluramine on body weight set-point: study in the rat with hoarding behaviour."
03/01/2007 - "There were significant decreases in body weight in the dexfenfluramine group (p < 0.05). "
12/01/2005 - "Body weights decrease and ileal contractile response of acethycholine increased significantly by dexfenfluramine treatment. "
05/01/1992 - "Despite such a cautionary note, and the expected need (at this stage of its development) for an expanded clinical study programme in certain areas, dexfenfluramine is a clear advance in the pharmacological approach to improved management of overweight individuals."
09/10/1998 - "We modified our randomized, double-blind, placebo-controlled study of dexfenfluramine to include echocardiographic examinations of 1072 overweight patients within a median of one month after the discontinuation of treatment. "
02/01/1993 - "Forty overweight patients in the Diabetic Clinic, Fremantle Hospital, were studied in a double-blind, placebo-controlled trial with a run-in period of one month followed by three months on either dexfenfluramine or placebo. "
05/01/1992 - "Studies in animal models and severely overweight patients have confirmed the effectiveness of dexfenfluramine as a weight-reducing agent which appears to be well tolerated. "
06/01/1992 - "The efficacy on bodyweight and the acceptability of a three month treatment with dexfenfluramine (Isoméride), combined with a prescribed diet, were evaluated in 336 women followed by a gynecologist for overweight. "
|2.||Drug Therapy (Chemotherapy)